Calmare Therapeutics Incorporated (OTCQX: CTTC) (CTI) maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Working across a broad spectrum of disciplines and industries, CTI provides distribution, patent and technology transfer, sales and licensing services to intellectual property owners seeking to commercialize their innovative products and technologies.

CTI has a world-class team of professionals with diverse technical, legal, intellectual property, marketing and business experience enabling it to offer a complete spectrum of solutions for the commercial optimization of technology. CTI works with universities, large and small corporations, and federal and private research centers in the U.S. and internationally.

CTI is the licensed distributor of the non-invasive Calmare® pain therapy medical device, which incorporates technology developed in Italy by CTI's client, to treat neuropathic pain, including cancer pain. For more information on the device, visit www.calmarett.com.

The Calmare® pain therapy device provides excellent pain treatment efficacy through a non-invasive procedure, which successfully treats pain without harmful side effects or the use of powerful and potentially addictive drugs.

Dr. Jonathan Kost, of the Hartford Hospital Pain Treatment Center, discusses use of the Calmare pain therapy device in the treatment of chemotherapy-induced peripheral neuropathy.